Drug intelligence / Profile preview

YanLiXiao

Development stage: Unknown
Lead developer: Global Pharmatech
Modality: Small Molecules
Administration: Oral

Overview

YanLiXiao is a traditional Chinese medicine (TCM) botanical product derived from the leaves of the clove plant (*Syringae Folium*). Developed by Global Pharmatech through its subsidiary Jilin BCT Pharmacy, it is primarily used to treat inflammatory and infectious conditions such as acute dysentery, enteritis, tonsillitis, and upper respiratory tract infections. The drug's therapeutic profile is attributed to iridoid glycosides, most notably syringopicroside, which exhibit potent antibacterial, anti-inflammatory, and detoxifying properties. It has demonstrated efficacy against various pathogens, including Methicillin-resistant *Staphylococcus aureus* (MRSA), and is commercially available in several Asian markets in oral forms like tablets and capsules.

Brand names: YanLiXiao
Other names: Syringae Folium extract

Beyond the preview

Go deeper on YanLiXiao.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YanLiXiao.

Explore the full profile